+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Divalproex Sodium Market by Form, Distribution Channel, Indication, Route of Administration, Dosage Strength - Global Forecast to 2030- Product Image
Divalproex Sodium Market by Form, Distribution Channel, Indication, Route of Administration, Dosage Strength - Global Forecast to 2030- Product Image
Sale

Divalproex Sodium Market by Form, Distribution Channel, Indication, Route of Administration, Dosage Strength - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6015503
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Divalproex Sodium Market grew from USD 2.47 billion in 2024 to USD 2.63 billion in 2025. It is expected to continue growing at a CAGR of 6.31%, reaching USD 3.57 billion by 2030.

Unveiling the Dynamics of Divalproex Sodium in Today’s Pharma Market

Divalproex Sodium has emerged as a cornerstone therapy in the management of diverse neurological and psychiatric disorders, carving out a distinct niche within the broader anticonvulsant landscape. Initially developed to address seizure control, its clinical applications have expanded to bipolar disorder and migraine prophylaxis, reflecting an evolving evidence base and growing physician confidence. As novel formulations and generics enter the fray, this compound’s market trajectory is increasingly shaped by technological, regulatory, and competitive forces.

This executive summary provides a panoramic overview of the factors influencing Divalproex Sodium adoption. Beginning with foundational developments in drug delivery and regulatory frameworks, it progresses through the transformative shifts reconfiguring supply chains and commercial strategies. Subsequent sections dissect the repercussions of the 2025 tariff adjustments in the United States, followed by a granular segmentation analysis that illuminates demand patterns across formulation types, distribution channels, indications, routes of administration, and dosage strengths. A regional breakdown then reveals strategic hotspots and nascent opportunities, while a competitive landscape assessment highlights the maneuvers of leading pharmaceutical players. The report concludes by offering actionable recommendations for industry leaders, underpinned by a robust research methodology that assures data integrity and analytical rigor.

Transformative Forces Reshaping the Divalproex Sodium Landscape

Pharmaceutical innovation, healthcare policy revisions, and patient-centric paradigms are collectively redefining the Divalproex Sodium market. Advances in drug delivery platforms, such as extended release technology and smart oral dosage forms, are elevating therapeutic adherence by smoothing plasma concentration profiles and reducing dosing frequency. Concurrently, heightened regulatory scrutiny is prompting manufacturers to invest in comprehensive pharmacovigilance programs and real-world evidence generation, fostering a more transparent and data-driven ecosystem.

The digital transformation of healthcare has further accelerated this shift. Telemedicine and e-pharmacy channels are broadening patient access, while artificial intelligence-driven analytics are optimizing clinical trial design and post-market surveillance. Moreover, personalized medicine initiatives are encouraging the segmentation of patient cohorts based on genetic biomarkers and comorbidity profiles, thereby influencing prescribing patterns. In tandem, intensifying generic competition has fueled price sensitivities, compelling innovator companies to differentiate through value-added services and patient support programs. These converging forces are collectively compelling stakeholders to reevaluate traditional go-to-market strategies and to embrace agile models that can respond swiftly to emerging trends and stakeholder expectations.

Assessing the Compound Effect of New US Tariffs on Market Dynamics

The imposition of new United States tariffs in 2025 has introduced a fresh set of variables for Divalproex Sodium manufacturers and distributors. Raw material costs have experienced an appreciable uptick as key active pharmaceutical ingredients face elevated import duties, exerting pressure on production budgets. Pharmaceutical companies are now recalibrating procurement strategies, with some shifting toward alternative suppliers in tariff-exempt jurisdictions or exploring domestic API synthesis to mitigate exposure.

These cost pressures are reverberating through the supply chain, prompting wholesalers and pharmacies to renegotiate pricing agreements and to reassess inventory management protocols to control working capital. Payer negotiations have become more complex, as insurers seek to offset increased reimbursements by imposing stricter utilization controls or encouraging lower-cost therapeutic alternatives. In response, manufacturers are implementing targeted patient assistance programs, co-pay support initiatives, and strategic partnerships with integrated delivery networks to preserve market share. Looking ahead, the tariff environment is likely to spur consolidation among smaller API suppliers and accelerate investments in regional manufacturing capabilities, underscoring the critical need for agile supply chain orchestration.

In-Depth Segmentation Reveals Diverse Demand Drivers

A meticulous segmentation analysis lays bare the heterogeneous nature of demand dynamics in the Divalproex Sodium market. Examined by form, the landscape encompasses capsules, injection, and tablets, with an escalating pivot toward extended release tablets that deliver steadier plasma levels over immediate release variants. Distribution channels present a similarly complex tapestry: hospital pharmacies remain pivotal for acute care settings, while online pharmacies have surged in prominence through both direct-to-consumer platforms and pharmacy e-commerce portals. Retail pharmacies, segmented into chain and independent outlets, continue to serve as vital touchpoints for chronic disease management and outpatient therapies.

Indication-based segmentation further refines market understanding, delineating usage across bipolar disorder, epilepsy, and migraine prophylaxis, each with distinct patient support needs and prescribing behaviors. Route of administration remains polarized between intravenous formulations for inpatient settings and oral therapies for outpatient regimens. Dosage strength segmentation highlights 125 mg, 250 mg, and 500 mg tiers, a structure that influences pack configuration, reimbursement strategy, and adherence initiatives. Synthesizing these dimensions reveals nuanced intersections-such as the preference for extended release tablets in outpatient epilepsy cohorts or the growth of e-commerce portals for migraine prophylaxis prescriptions-guiding targeted investment and marketing decisions.

Regional Variances Highlight Strategic Market Opportunities

Regional analysis underscores divergent growth trajectories and strategic imperatives across the global market. In the Americas, robust research infrastructures, favorable reimbursement frameworks, and high patient awareness support a mature and competitive environment. Market incumbents leverage real-world evidence studies and comprehensive patient support programs to maintain penetration and defend pricing power. Conversely, Europe, the Middle East & Africa navigate a spectrum of reimbursement models and regulatory regimes, where price controls and tender‐based procurement shape manufacturer strategies and encourage portfolio diversification to balance high-margin and volume-driven segments.

Asia-Pacific is characterized by rapidly expanding healthcare access, rising incidence of epilepsy and bipolar disorder, and accelerating generic penetration. Emerging markets within this region are investing in upgraded healthcare facilities and decentralized distribution networks, driving uptake of both oral and injectable regimens. As local manufacturers scale up capacity and forge partnerships with global innovators, the region is poised to evolve from a predominantly cost-sensitive market to a hotspot for clinical trials, pharmacovigilance studies, and specialty formulation development. Stakeholders must tailor market entry and expansion plans to regional nuances, balancing price competitiveness with value creation strategies.

Competitive Landscape Spotlight on Leading Pharmaceuticals

The competitive arena for Divalproex Sodium is marked by a blend of multinational pharmaceutical giants, established generic manufacturers, and emerging biotech firms. Leading players have fortified their positions through strategic acquisitions of niche formulators and expansion of production capacities for extended release platforms. Generic specialists, leveraging economies of scale and streamlined production processes, are applying rigorous cost optimization efforts to capture price-sensitive segments, particularly in the hospital and retail pharmacy channels.

Collaborations between research institutions and industry stakeholders are accelerating the development of novel delivery systems and branded generics, while in-licensing agreements are providing access to innovative excipient technologies. Some companies are differentiating their offerings through integrated patient support ecosystems, encompassing digital adherence tools, educational resources, and co-pay assistance. Meanwhile, license partnerships in emerging economies are facilitating market entry for global players and enabling local companies to enhance their product portfolios. This fluid competitive environment demands continuous monitoring of partnership announcements, patent expiration timelines, and regulatory filings to identify white spaces and anticipate shifts in market share.

Strategic Recommendations to Capitalize on Market Growth

Industry leaders should prioritize the development and commercialization of extended release oral formulations that improve patient adherence and differentiate offerings in a commoditized market. Simultaneously, diversifying API sourcing by forging alliances with geographically dispersed suppliers can mitigate tariff risk and bolster supply chain resilience. Augmenting direct engagement with healthcare providers and payers via value demonstration studies will support favorable formulary positioning and reimbursement access, especially in markets with stringent cost controls.

Digital engagement platforms represent another growth frontier; investing in telehealth partnerships and pharmacy e-commerce capabilities can unlock new patient segments, particularly for migraine prophylaxis and outpatient epilepsy management. Collaborative ventures with contract manufacturing organizations and in-licensing deals for novel excipients or delivery technologies can accelerate portfolio expansion while containing R&D expenditure. Lastly, regional market entries should be guided by tailored pricing strategies and patient assistance initiatives, ensuring alignment with local healthcare financing mechanisms and enhancing brand equity among key stakeholders.

Robust Methodology Ensuring Data Integrity and Insightful Analysis

This report’s insights are underpinned by a rigorous methodology combining primary and secondary research. Extensive interviews with C-suite executives, clinical experts, regulatory authorities, and distribution channel leaders have provided firsthand perspectives on market dynamics. Secondary data sources include peer-reviewed journals, industry white papers, regulatory filings, and proprietary healthcare databases, ensuring comprehensive coverage and cross-validation of critical inputs.

Quantitative models have been constructed through meticulous data triangulation, reconciling diverging estimates and normalizing for currency and regional variances. Quality assurance measures involve iterative peer reviews, methodological audits, and sensitivity analyses to test the robustness of key findings. Segmentation frameworks were crafted to capture multifaceted demand drivers, while regional assessments were calibrated against geopolitical, economic, and healthcare policy indicators. This systematic approach guarantees the integrity, transparency, and actionability of the research deliverables.

Conclusion Emphasizing the Imperative for Informed Decision-Making

In a market characterized by evolving regulatory landscapes, shifting supply chain paradigms, and fierce competitive rivalry, informed decision-making is paramount. Divalproex Sodium’s role across epilepsy, bipolar disorder, and migraine prophylaxis underscores its strategic importance, while segmentation and regional analyses reveal targeted pathways for growth and differentiation. The 2025 tariff developments add a layer of complexity, compelling stakeholders to reinforce supply chain agility and cost-management frameworks.

By aligning product development, commercial strategies, and regional expansion plans with the market’s nuanced demand drivers, industry participants can unlock new value streams and sustain competitive advantage. Embracing digital transformation, forging strategic alliances, and investing in patient-centric programs will differentiate offerings in both mature and emerging markets. Ultimately, this comprehensive overview equips executives with the insights needed to chart a proactive course in the dynamic Divalproex Sodium landscape, fostering resilient growth and long-term success.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Form
    • Capsules
    • Injection
    • Tablets
      • Extended Release Tablets
      • Immediate Release Tablets
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
      • Direct To Consumer Platform
      • Pharmacy E-Commerce Platform
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • Indication
    • Bipolar Disorder
    • Epilepsy
    • Migraine Prophylaxis
  • Route Of Administration
    • Intravenous
    • Oral
  • Dosage Strength
    • 125 Mg
    • 250 Mg
    • 500 Mg
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Fresenius Kabi AG
  • Hetero Drugs Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Divalproex Sodium Market, by Form
8.1. Introduction
8.2. Capsules
8.3. Injection
8.4. Tablets
8.4.1. Extended Release Tablets
8.4.2. Immediate Release Tablets
9. Divalproex Sodium Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.3.1. Direct to Consumer Platform
9.3.2. Pharmacy E-Commerce Platform
9.4. Retail Pharmacy
9.4.1. Chain Pharmacy
9.4.2. Independent Pharmacy
10. Divalproex Sodium Market, by Indication
10.1. Introduction
10.2. Bipolar Disorder
10.3. Epilepsy
10.4. Migraine Prophylaxis
11. Divalproex Sodium Market, by Route of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Divalproex Sodium Market, by Dosage Strength
12.1. Introduction
12.2. 125 Mg
12.3. 250 Mg
12.4. 500 Mg
13. Americas Divalproex Sodium Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Divalproex Sodium Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Divalproex Sodium Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Teva Pharmaceutical Industries Ltd.
16.3.3. Viatris Inc.
16.3.4. Sandoz International GmbH
16.3.5. Sun Pharmaceutical Industries Ltd.
16.3.6. Dr. Reddy's Laboratories Limited
16.3.7. Aurobindo Pharma Limited
16.3.8. Cipla Limited
16.3.9. Fresenius Kabi AG
16.3.10. Hetero Drugs Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. DIVALPROEX SODIUM MARKET MULTI-CURRENCY
FIGURE 2. DIVALPROEX SODIUM MARKET MULTI-LANGUAGE
FIGURE 3. DIVALPROEX SODIUM MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DIVALPROEX SODIUM MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. DIVALPROEX SODIUM MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. DIVALPROEX SODIUM MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DIVALPROEX SODIUM MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DIVALPROEX SODIUM MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EXTENDED RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY IMMEDIATE RELEASE TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DIRECT TO CONSUMER PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY PHARMACY E-COMMERCE PLATFORM, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY MIGRAINE PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 125 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 250 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DIVALPROEX SODIUM MARKET SIZE, BY 500 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DIVALPROEX SODIUM MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 52. CANADA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 53. CANADA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 54. CANADA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. CANADA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 56. CANADA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 57. CANADA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. CANADA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 60. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 61. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 63. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 64. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 65. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 66. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. MEXICO DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 88. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 89. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 93. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 94. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 95. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 97. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 98. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. UNITED KINGDOM DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 101. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 102. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 103. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 105. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 106. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. GERMANY DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 109. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 110. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 111. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 113. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 114. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 115. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. FRANCE DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 117. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 122. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 123. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 125. ITALY DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 126. ITALY DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 127. ITALY DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. ITALY DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 129. ITALY DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 130. ITALY DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 131. ITALY DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 132. ITALY DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 133. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 134. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 135. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 136. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 137. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 138. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 139. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 140. SPAIN DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 143. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED ARAB EMIRATES DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 149. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 150. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 151. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 153. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 154. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 156. SAUDI ARABIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 157. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 158. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 165. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 166. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 167. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 169. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 170. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 171. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 174. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 175. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 177. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 178. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. NETHERLANDS DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 181. QATAR DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 182. QATAR DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 183. QATAR DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 184. QATAR DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 185. QATAR DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 186. QATAR DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 187. QATAR DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 189. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 190. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 191. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 193. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 194. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. FINLAND DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 197. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 198. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 199. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 201. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 204. SWEDEN DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 210. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 211. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 212. NIGERIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 213. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 214. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 215. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 217. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 218. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 219. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 220. EGYPT DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 221. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 222. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 223. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 224. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 225. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 226. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. TURKEY DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 229. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 230. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 231. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 232. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 233. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 234. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 236. ISRAEL DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 237. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 238. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 239. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 241. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 242. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 243. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NORWAY DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 245. POLAND DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 246. POLAND DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 247. POLAND DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 248. POLAND DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 249. POLAND DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 250. POLAND DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. POLAND DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. POLAND DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 261. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 262. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 263. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 265. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 266. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 267. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 268. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DIVALPROEX SODIUM MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 270. CHINA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 271. CHINA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 272. CHINA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. CHINA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 274. CHINA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 275. CHINA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 276. CHINA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 277. CHINA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 278. INDIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 279. INDIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 280. INDIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. INDIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 282. INDIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 283. INDIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 284. INDIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. INDIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 286. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 287. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 288. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 289. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 290. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 291. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 292. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. JAPAN DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 294. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 295. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 296. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 297. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 298. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 299. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 300. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 301. AUSTRALIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 302. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 303. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 304. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 305. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 306. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 307. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 308. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 309. SOUTH KOREA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 310. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 311. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 312. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 314. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 315. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 316. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. INDONESIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 318. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 319. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 320. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 321. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 322. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 323. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 324. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 325. THAILAND DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 326. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 327. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 328. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 329. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 330. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 331. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 332. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 333. PHILIPPINES DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA DIVALPROEX SODIUM MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 342. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY FORM, 2018-2030 (USD MILLION)
TABLE 343. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 344. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 346. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 347. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 348. SINGAPORE DIVALPROEX SODIUM MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 349. SINGAP

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Divalproex Sodium market report include:
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Limited
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Fresenius Kabi AG
  • Hetero Drugs Limited

Table Information

Report AttributeDetails
No. of Pages194
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 2.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 3.57 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Anticonvulsants Market Report 2025 - Product Image

Anticonvulsants Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Seizures Pipeline Insight Analysis Report - Product Image

Seizures Pipeline Insight Analysis Report

  • Drug Pipelines
  • 150 Pages
  • Global
From
Grand Mal Seizure Treatment Market Report 2025 - Product Image

Grand Mal Seizure Treatment Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Anticonvulsants Market by Drug Class, Indication, Route Of Administration, Distribution Channel, Formulation - Global Forecast to 2030 - Product Image

Anticonvulsants Market by Drug Class, Indication, Route Of Administration, Distribution Channel, Formulation - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030 - Product Image

Dravet Syndrome Market by Drug Class, End User, Distribution Channel, Route of Administration, Patient Age Group - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From

About the Divalproex Sodium Market

Divalproex Sodium is a drug used to treat various conditions related to the Central Nervous System (CNS). It is an anticonvulsant and mood stabilizer used to treat epilepsy, bipolar disorder, and migraine headaches. It is also used to treat certain psychiatric disorders, such as schizophrenia and schizoaffective disorder. Divalproex Sodium is available in both immediate-release and extended-release formulations. The extended-release formulation is used to treat manic episodes associated with bipolar disorder. Divalproex Sodium is a widely used drug in the CNS market. It is generally well-tolerated and has a low risk of side effects. It is also relatively inexpensive compared to other CNS drugs. Some companies in the Divalproex Sodium market include AbbVie, Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.